Edition:
United Kingdom

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

54.15USD
3:40pm GMT
Change (% chg)

$0.46 (+0.86%)
Prev Close
$53.69
Open
$53.81
Day's High
$54.15
Day's Low
$53.81
Volume
8,879
Avg. Vol
54,696
52-wk High
$54.15
52-wk Low
$20.30

Select another date:

Wed, Jan 3 2018

BRIEF-Ascendis Pharma Says Completed Target Enrollment In Phase 3 Trial Of Pediatric Growth Hormone Deficiency Treatment

* ASCENDIS PHARMA ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 3 TRIAL OF TRANSCON GROWTH HORMONE FOR PEDIATRIC GROWTH HORMONE DEFICIENCY

BRIEF-Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP

* ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING Source text : (http://bit.ly/2BTTLso) Further company coverage:

BRIEF-Ascendis Pharma A/S Q3 loss per share EUR 1.04

* Ascendis Pharma A/S reports third quarter 2017 financial results

BRIEF-Ascendis Pharma A/S prices public offering of 3.8 mln shares at $35.50 per ADS

* Ascendis Pharma A/S announces pricing of public offering of ADSs

BRIEF-Ascendis Pharma A/S announces proposed public offering of ADSs

* Ascendis Pharma A/S announces proposed public offering of ADSs

BRIEF-Ascendis Pharma A/S reports dosing of subjects in phase 1 trial of transcon pth

* Ascendis Pharma A/S announces dosing of subjects in phase 1 trial of Transcon pth

BRIEF-Ascendis Pharma Q2 loss per share EUR 0.94

* Ascendis Pharma A/S reports second quarter 2017 financial results

Select another date: